Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: combined results from 382 subjects in the phase 2b study U-ACHIEVE

(1) University of Michigan,Ann Arbor,United States

(2) Service de Gastro-Entérologie et Nutrition Clinique, Université de Nice-Sophia-Antipolis,Nice,France

(3) University of Alberta,Edmonton,Canada

(4) AbbVie Inc.,Chicago,United States

(5) Istituto Clinico Humanitas,Milan,Italy

This item was part of the Lower GI on fire session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019